Immunogenicity and Safety of a Single Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi
Most Recent Events
- 16 Nov 2020 Status changed from active, no longer recruiting to completed.
- 14 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Nov 2020.
- 14 Oct 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2020.